You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Boehringer Ingelheim
Moodys
Medtronic
Baxter

Last Updated: February 21, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,579,865


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,579,865 protect, and when does it expire?

Patent 8,579,865 protects OTREXUP and is included in one NDA.

This patent has twelve patent family members in seven countries.

Summary for Patent: 8,579,865
Title:Hazardous agent injection system
Abstract: Injection systems comprising a powered injector and one or more hazardous agents are disclosed.
Inventor(s): Wotton; Paul (Stamford, CT), Sadowski; Peter L. (Woodbury, MN), Hayes; John William (Chaska, MN)
Assignee: Antares Pharma, Inc. (Ewing, NJ)
Application Number:13/257,555
Patent Claim Types:
see list of patent claims
Dosage form; Use;

Drugs Protected by US Patent 8,579,865

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-005 Nov 7, 2014 DISCN Yes No   Start Trial   Start Trial Y SUBCUTANEOUS INJECTION OF METHOTREXATE   Start Trial
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-001 Oct 11, 2013 RX Yes Yes   Start Trial   Start Trial Y SUBCUTANEOUS INJECTION OF METHOTREXATE   Start Trial
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-006 Mar 24, 2016 RX Yes Yes   Start Trial   Start Trial Y SUBCUTANEOUS INJECTION OF METHOTREXATE   Start Trial
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-002 Oct 11, 2013 RX Yes Yes   Start Trial   Start Trial Y SUBCUTANEOUS INJECTION OF METHOTREXATE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,579,865

PCT Information
PCT FiledMarch 19, 2010PCT Application Number:PCT/US2010/028011
PCT Publication Date:September 23, 2010PCT Publication Number: WO2010/108116

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
AstraZeneca
Johnson and Johnson
Moodys
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.